Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023
In response to the mpox outbreak in 2022 and 2023, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as JYNNEOS or Imvanex) was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralising antibodies waned to undetectable levels 1 year post vaccination in at-risk individuals who received two doses of MVA-BN administered subcutaneously with an interval of 4 weeks, without prior smallpox or mpox vaccination. Continuous surveillance is essential to understand the impact of declining antibody levels.
Authors
- Leanne P. M. van Leeuwen (ORCID: https://orcid.org/0000-0001-9762-6381)
- Martin E. van Royen (ORCID: https://orcid.org/0000-0002-6814-0996)
- Hannelore M Götz (ORCID: https://orcid.org/0000-0002-1236-6224)
- Marion Koopmans (ORCID: https://orcid.org/0000-0002-5204-2312)
- Susanne Bogers (ORCID: https://orcid.org/0000-0002-8212-2946)
- Rory D. de Vries (ORCID: https://orcid.org/0000-0003-2817-0127)
- Corine H. GeurtsvanKessel (ORCID: https://orcid.org/0000-0002-7678-314X)
- Babs E. Verstrepen (ORCID: https://orcid.org/0000-0002-4666-0798)
- Marc C. Shamier (ORCID: https://orcid.org/0000-0002-3421-6833)
- Katharina S. Schmitz (ORCID: https://orcid.org/0000-0002-8537-0646)
- Luca M. Zaeck (ORCID: https://orcid.org/0000-0001-7997-493X)
- Koen Wijnans
- Najlae Akhiyate
- Eric CM van Gorp
Institutions
- Erasmus MC (NL)
- GGD Rotterdam-Rijnmond (NL)
Publication Details
- Journal
- Eurosurveillance
- Published
- 2024-09-19
- DOI
- https://doi.org/10.2807/1560-7917.es.2024.29.38.2400575
- Citations
- 17
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 4.99
Funders
- European Commission
- ZonMw
- Horizon 2020 Framework Programme